

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

CLINICAL TRIAL NOTICES OF “HS-10386 TABLETS” AND “HS-10384 TABLETS”

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that “HS-10386 tablets”, a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.* (江蘇豪森藥業集團有限公司) and Shanghai Hansoh Biomedical Co., Ltd.* (上海翰森生物醫藥科技有限公司) (“**Shanghai Hansoh**”), both subsidiaries of the Company, and “HS-10384 tablets”, a Category 1 innovative drug self-developed by Changzhou Hansoh Pharmaceutical Co., Ltd.* (常州恒邦藥業有限公司), another subsidiary of the Company, and Shanghai Hansoh, have been granted clinical trial notices issued by the National Medical Products Administration of the People’s Republic of China. “HS-10386 tablets” is intended to be used for the treatment of advanced solid tumors and “HS-10384 tablets” is intended to be used for menopausal vasomotor syndrome. Their specific indications will be determined after the completion of clinical research.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, April 27, 2022

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* For identification purposes only